Agios board member David Schenkein resigns effective Feb 28, 2025; stays as strategic advisor

AGIOS PHARMACEUTICALS, INC.

Dr. Schenkein notified company of resignation from board on Feb 10, 2025, effective Feb 28, 2025.
He will also cease serving on the Science and Technology Committee of the board.
He will continue as a strategic advisor to leadership, focusing on advancing clinical development programs.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David P. Schenkein, M.D.

Director

AGIO · AGIOS PHARMACEUTICALS, INC.

Effective: 2025-02-28
Filed: February 13, 2025, 6:59 PM ET

On February 10, 2025, David P. Schenkein, M.D., notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”), effective February 28, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David P. Schenkein, M.D. resigned as Director at AGIOS PHARMACEUTICALS, INC..

Action: resigned
Role: Director

Exact text from the filing

On February 10, 2025, David P. Schenkein, M.D., notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”), effective February 28, 2025.

View on SEC.gov

AGIOS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-25-025524

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.